Xacduro® (sulbactam; durlobactam) – New drug approval
May 23, 2023 - The FDA announced the approval of Innoviva Specialty Therapeutics’ Xacduro (sulbactam; durlobactam), in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (A. baumannii).
Top